Approved (FDA) as single agent since 2016 in advanced BRCA mutated/HRD ovarian cancer BRCA mutated mCRPC (2020).Phase III as single agent in ovarian cancer, BRCA or ATM mutated mCRPC. In combination with nivolumab in ovarian cancer, with enzalutamide in mCRPC. This evidence concerns the gene ATM and ovarian cancer.